Lilly acquires three infectious disease companies for up to $3.83 billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- S&P 500 muted as industrials counter tech drag; US-Iran peace prospects rise
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Lilly announces three acquisitions to build infectious disease portfolio
May 26, 2026 6:45 AM EDTAgreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat
Acquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious disease
INDIANAPOLIS, May 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:Â LLY) today announced agreements to... More
